Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 7-arm NCT04868877

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Sponsor: Merus B.V.

Conditions Colorectal Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Head and Neck Squamous Cell Carcinoma Non-Small Cell Lung Cancer Metastatic

Interventions Chemotherapy MCLA-129 Osimertinib

Updated 12 times since 2021 Last updated: Feb 17, 2026 Started: Apr 28, 2021 Primary completion: Mar 31, 2026 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Colorectal Cancer and Esophageal Squamous Cell Carcinoma and is currently ongoing. Merus B.V. leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2025 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 7 earlier versions

Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2021 — Feb 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merus B.V.

Data source: Merus B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Amsterdam, Netherlands , Anderlecht, Belgium , Barcelona, Spain , Bologna, Italy , Bordeaux, France , Brescia, Italy , Bron, France , Créteil, France , Edegem, Belgium and 26 more locations